查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2020216

荷尔蒙补充疗法市场规模、份额、成长及全球产业分析：按类型、应用和地区划分，并预测至2026-2034年

Hormone Replacement Therapy Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 138 Pages | 商品交期: 请询问到货日

价格

荷尔蒙补充疗法（HRT）市场的成长要素

受更年期症状、生长激素缺乏症、甲状腺机能低下症和男性性腺功能低下症患病率上升的推动，全球荷尔蒙补充疗法（HRT）市场正经历显着增长。根据财富商业洞察（Fortune Business Insights）的数据显示，2025年HRT市场规模为179.4亿美元。预计到2026年，该市场规模将成长至190.4亿美元，2034年进一步扩大至312.3亿美元，预测期内复合年增长率（CAGR）为6.38%。

市场动态

荷尔蒙补充疗法）不仅对治疗女性更年期症状（如潮热、睡眠障碍、焦虑和骨质疏鬆）至关重要，而且对治疗男性和儿童的荷尔蒙相关疾病也同样重要。例如，生长激素缺乏症、甲状腺机能低下症以及男性和儿童的男性性腺功能低下症，都在推动全球对HRT的采用。人们对现代治疗方法的认识不断提高，以及对雌激素疗法、联合治疗、经皮和口服製剂的接受度不断提高，都是推动市场扩张的关键因素。

新冠疫情期间，该市场曾经历短暂下滑，主要原因是供不应求以及医疗机构营运中断影响了诊断和治疗。然而，随着医疗服务的重新开放以及对这些疗法的持续需求，市场成长已恢復至疫情前水准。

市场区隔

治疗方法：

  • 雌激素及联合治疗：在人们对更年期症状的认识不断提高以及凝胶、贴剂和口服片剂等多种剂型的普及推动下，预计到2026年，雌激素及联合疗法将占据全球51.04%的市场份额，引领市场。 Theramex公司在欧洲和英国推出的「Bijuva/Bijuve」等知名新产品正在加速市场成长。
  • 荷尔蒙补充疗法（GHRT）：由于生长激素缺乏症盛行率不断上升，预计该疗法将实现较高的复合年增长率。诺和诺德的诺德促生长素（Norditropin）和辉瑞/OPKO Health的索马托洛根（Somatologun）等产品正在推动销售成长。
  • 睾酮疗法：随着 Jatenzo（口服睾酮）和 Tlando 等药物的核准，男性性腺功能低下症的治疗选择正在扩大，预计未来将稳步增长。
  • 甲状腺荷尔蒙补充疗法：甲状腺机能低下症盛行率的增加以及 Thyquidity（VistaPharm，2020 年获得 FDA核准）等新产品的核准，推动了该领域的成长。

透过申请：

  • 更年期：到 2026 年，这将成为最大的细分市场，占市场份额的 56.8%，这主要得益于全球更年期女性人数的增加以及对雌激素和孕激素疗法的需求不断增长。
  • 甲状腺机能低下症：由于甲状腺疾病的盛行率不断上升，这是第二大细分市场。
  • 生长激素缺乏症：这是一个全球性的主要问题，美国每年报告约有 6,000 例新的成人病例。
  • 男性性腺功能低下症：在美国，有 400 万至 500 万名男性患有这种疾病，而新的睪固酮疗法的普及程度正在提高。

依管理途径：

  • 口服给药：由于其渗透率高、生产规模大，已成为全球主流的给药方式。
  • 由于凝胶和贴剂的使用降低了口服治疗的风险，经皮给药方式得到了显着发展。
  • 肠外给药：预计这将导致最低的生长速度。

按分销管道：

  • 医院药局：这是最广泛采用的药局类型，因为它们位于综合医院内，确保了药品的可靠供应。
  • 普通药局：在非处方荷尔蒙替代疗法产品的支持下，它们做出了第二大贡献。
  • 受人们对便利性和安全性的担忧推动，网路药局发展迅速，尤其是在疫情期间。

区域趋势

  • 北美：预计到2025年将占据52.12%的市场份额，市场规模为93.5亿美元，预计到2026年将达到99亿美元。美国市场预计到2026年将达到84.5亿美元。更年期疾病、男性性腺功能低下症和生长激素缺乏症的高发生率，以及高昂的医疗保健成本，是推动市场成长的主要因素。
  • 欧洲：预计到 2025 年市场规模将达到 30.2 亿美元，到 2026 年将成长至 31.8 亿美元。英国和德国是主要市场，女性荷尔蒙失调和老年人甲状腺机能低下症的增加推动了需求成长。
  • 亚太地区：预计到 2025 年市场规模将达到 30.3 亿美元，到 2026 年将达到 32.7 亿美元。成长动力包括人们对停经后风险的认识不断提高、未满足的需求以及中国和日本核准的新治疗方法。
  • 拉丁美洲和中东及非洲：预计到 2025 年，市场份额将相对较小（分别为 11.4 亿美元和 14 亿美元），并且由于认知度低和需求未得到满足，预计增长缓慢。

市场趋势和成长要素

  • 先进药物传输系统（如经皮吸收贴片、凝胶和低剂量雌激素製​​剂）的引入，正在推动市场扩张。
  • 随着人们对个人化医疗和精准荷尔蒙疗法的关注度不断提高，考虑到遗传因素、生活方式和荷尔蒙水平的客製化治疗方案正变得越来越可靠。
  • 全球更年期症状和生长激素缺乏症的日益普遍，正在推动新产品的开发和研发。
  • 生物同源荷尔蒙疗法和生物相容性化合物产品（如 Bijuva/Bijuve）等创新技术提高了安全性和有效性。

抑制因子

  • 血栓、胆固醇水平变化、心血管风险和前列腺问题等副作用可能会限制其使用。
  • 高昂的治疗费用是一个障碍，尤其是对于没有保险的患者而言。
  • 监管挑战、FDA核准延迟以及产品召回（例如 Dr. Reddy 的孕酮胶囊、Perrigo 的 Evamist 喷雾剂）可能会阻碍市场成长。

成长率：2026年至2034年的复合年增长率为6.38%。

透过治疗方法

  • 雌激素和联合治疗
  • 甲状腺荷尔蒙补充疗法
  • 生长激素荷尔蒙补充疗法
  • 睪固酮荷尔蒙补充疗法

适应

  • 停经
  • 甲状腺机能低下症
  • 男性性腺功能低下症
  • 生长激素缺乏症

透过行政途径

  • 口服
  • 经皮
  • 肠外

透过分销管道

  • 医院药房
  • 零售药局和药房
  • 网路药房

按地区

  • 北美（按治疗方法、适应症、给药途径、分销管道和国家/地区划分）
    • 我们
    • 加拿大
  • 欧洲（依治疗领域、适应症、给药途径、通路和国家/次区域划分）
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪地那维亚
    • 其他欧洲国家
  • 亚太地区（依治疗方法、适应症、给药途径、通路和国家/次区域划分）
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 东南亚
    • 亚太其他地区
  • 拉丁美洲（依治疗方法、适应症、给药途径、通路和国家/次区域划分）
    • 巴西
    • 墨西哥
    • 其他拉丁美洲
  • 中东和非洲（按治疗方法、适应症、给药途径、分销管道和国家/次区域划分）
    • GCC
    • 南非
    • 其他中东和非洲地区

目录

第一章：引言

第二章执行摘要

第三章 市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场趋势

第四章：主要考虑因素

  • 主要企业管道分析
  • 产业重大发展动态－併购与合作
  • 新产品发布：按主要企业划分
  • 新冠疫情的影响：全球荷尔蒙补充疗法市场

第五章：全球荷尔蒙补充疗法市场分析、洞察与预测（2021-2034年）

  • 市场分析、洞察与预测：按治疗方法
    • 雌激素和联合荷尔蒙补充疗法
    • 甲状腺荷尔蒙补充疗法
    • 生长激素荷尔蒙补充疗法
    • 睪固酮荷尔蒙补充疗法
  • 市场分析、洞察与预测：按适应症划分。
    • 停经
    • 甲状腺机能低下症
    • 男性性腺功能低下症
    • 生长激素缺乏症
  • 市场分析、洞察与预测：按给药途径
    • 口服
    • 经皮
    • 肠外
  • 市场分析、洞察与预测：按分销管道划分
    • 医院和药房
    • 零售药局和药房
    • 网路药房
  • 市场分析、洞察与预测：按地区划分
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章：北美荷尔蒙补充疗法市场分析、洞察与预测（2021-2034年）

  • 国家
    • 我们
    • 加拿大

第七章：欧洲荷尔蒙补充疗法市场分析、洞察与预测（2021-2034年）

  • 国家
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 斯堪地那维亚
    • 其他欧洲国家

第八章：亚太地区荷尔蒙补充疗法市场分析、洞察与预测（2021-2034年）

  • 国家
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 东南亚
    • 其他亚太国家

第九章：拉丁美洲荷尔蒙补充疗法市场分析、洞察与预测（2021-2034年）

  • 国家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲国家

第十章：中东和非洲荷尔蒙补充疗法市场分析、洞察与预测（2021-2034年）

  • 国家
    • GCC
    • 南非
    • 其他中东和非洲国家

第十一章 竞争分析

  • 全球市占率分析（2026 年）
  • 公司简介
    • Novo Nordisk A/S
    • Pfizer Inc.
    • AbbVie Inc.
    • Merck KGaA
    • Endo Pharmaceuticals Solutions Inc.
    • Allergan
    • Eli Lilly and Company
    • Mithra Pharmaceuticals
    • Amgen
Product Code: FBI102543

Growth Factors of hormone replacement therapy (HRT) Market

The global hormone replacement therapy (HRT) market is witnessing substantial growth, driven by the rising prevalence of menopausal disorders, growth hormone deficiencies, hypothyroidism, and male hypogonadism. According to Fortune Business Insights, the HRT market size was valued at USD 17.94 billion in 2025. The market is projected to grow to USD 19.04 billion in 2026 and further expand to USD 31.23 billion by 2034, reflecting a CAGR of 6.38% during the forecast period.

Market Dynamics

Hormone replacement therapies are critical for treating menopause-related symptoms in women, including hot flashes, sleep disorders, anxiety, and osteoporosis, as well as hormone-related deficiencies in men and children. For instance, growth hormone deficiency in adults and pediatric populations, hypothyroidism, and male hypogonadism are all driving the adoption of HRT globally. The growing awareness of modern therapies and increased acceptance of estrogen and combination therapy, as well as transdermal and oral formulations, are key factors supporting market expansion.

The market faced temporary setbacks during the COVID-19 pandemic, primarily due to shortages in supply and disruptions in healthcare facilities, which impacted diagnosis and treatment. However, resumption of healthcare services and continued demand for these therapies have restored growth to pre-pandemic levels.

Market Segmentation

By Therapy Type:

  • Estrogen and Combination Therapy: Dominates the market with a projected 51.04% share globally in 2026, driven by awareness of menopausal symptoms and availability of multiple formulations such as gels, patches, and oral tablets. Notable product launches, including Bijuva/Bijuve by Theramex in Europe and the UK, are propelling growth.
  • Growth Hormone Replacement Therapy (GHRT): Expected to witness strong CAGR due to rising prevalence of growth hormone deficiencies. Products like Norditropin (Novo Nordisk) and somatrogon (Pfizer/OPKO Health) are leading in revenue growth.
  • Testosterone Therapy: Steady growth expected with approvals like Jatenzo (oral testosterone) and Tlando enhancing male hypogonadism treatment options.
  • Thyroid Hormone Replacement Therapy: Growth is supported by increasing hypothyroidism prevalence and new product approvals, such as Thyquidity (VistaPharm, FDA-approved in 2020).

By Indication:

  • Menopause: Largest segment with 56.8% market share in 2026, driven by the growing global population of menopausal women and increasing demand for estrogen-progesterone therapy.
  • Hypothyroidism: Second-largest segment due to rising thyroid disorder prevalence.
  • Growth Hormone Deficiency: A significant concern worldwide, with approximately 6,000 new adult cases annually in the U.S.
  • Male Hypogonadism: Affecting 4-5 million men in the U.S., treatment adoption is increasing with new testosterone therapies.

By Route of Administration:

  • Oral: Dominates globally due to widespread adoption and mass production.
  • Transdermal: Growing significantly due to gel and patch formulations reducing risks associated with oral therapy.
  • Parenteral: Expected to grow at the lowest rate.

By Distribution Channel:

  • Hospital Pharmacies: Largest adoption due to the presence of pharmacies in multispecialty hospitals, ensuring therapy availability.
  • Retail Pharmacies: Second-largest contributor, supported by over-the-counter HRT products.
  • Online Pharmacies: Witnessing rapid growth, especially post-pandemic, driven by convenience and safety concerns.

Regional Insights

  • North America: Dominates the market with 52.12% share in 2025, valued at USD 9.35 billion, projected to reach USD 9.9 billion in 2026. U.S. market expected to reach USD 8.45 billion in 2026. Growth driven by high prevalence of menopause, male hypogonadism, growth hormone deficiency, and high healthcare expenditure.
  • Europe: Valued at USD 3.02 billion in 2025, projected to grow to USD 3.18 billion in 2026. The UK and Germany are key markets, with rising hormonal disorders in women and geriatric hypothyroidism driving demand.
  • Asia Pacific: Market size of USD 3.03 billion in 2025, expected to reach USD 3.27 billion in 2026. Growth fueled by increased awareness of post-menopausal hazards, unmet medical needs, and novel therapy approvals in China and Japan.
  • Latin America and Middle East & Africa: Smaller market share in 2025 (USD 1.14 billion and USD 1.4 billion, respectively), projected for moderate growth due to low awareness and unmet needs.

Market Trends and Growth Factors

  • Launch of advanced drug delivery systems, such as transdermal patches, gels, and low-dose estrogen formulations, is driving market expansion.
  • Increasing focus on personalized medicine and precision hormone therapy ensures tailored treatments considering genetics, lifestyle, and hormone levels.
  • Rising prevalence of menopausal symptoms and growth hormone deficiency globally is encouraging new product development and R&D.
  • Innovations like bioidentical hormone therapies and body-identical combination products, such as Bijuva/Bijuve, enhance safety and efficacy.

Restraining Factors

  • Adverse effects, including blood clots, cholesterol changes, cardiovascular risks, and prostate issues, may limit adoption.
  • High therapy costs, particularly for uninsured patients, pose a barrier.
  • Regulatory challenges, delayed FDA approvals, and product recalls (e.g., Dr. Reddy's progesterone capsules, Perrigo Evamist spray) may impede growth.

Competitive Landscape

Key players in the global HRT market include:

  • Novo Nordisk A/S (Denmark) - Leading with Norditropin and Sogroya for growth hormone deficiencies.
  • Pfizer Inc. (U.S.) - Known for Genotropin and somatrogon development.
  • AbbVie, Merck KGaA, Endo International, Allergan, Eli Lilly, Mithra Pharmaceuticals, Amgen - Active in product launches, approvals, and R&D.

Notable Developments:

  • June 2023 - Pfizer reintroduced DUAVEE with enhanced packaging.
  • June 2022 - Launch of Tlando (oral testosterone) in the U.S.
  • May 2021 - Myovant Sciences received FDA approval for Myfembree.
  • April 2021 - BIJUVE approved in U.K. and Belgium.
  • October 2020 - Positive Phase 3 results for somatrogon in pediatric growth hormone deficiency.

Conclusion

The global hormone replacement therapy market is on a strong growth trajectory, expanding from USD 17.94 billion in 2025 to USD 31.23 billion by 2034, driven by increasing hormonal disorders, aging populations, and technological innovations in drug delivery. North America continues to lead the market, while Asia Pacific presents emerging opportunities. The combination of advanced therapies, personalized medicine, and strong R&D initiatives by key players like Novo Nordisk and Pfizer is expected to sustain long-term growth, despite challenges such as side effects, high costs, and regulatory hurdles.

Growth Rate CAGR of 6.38% from 2026-2034

By Therapy Type

  • Estrogen and Combinations Replacement Therapy
  • Thyroid Hormone Replacement Therapy
  • Growth Hormone Replacement Therapy
  • Testosterone Hormone Replacement Therapy

By Indication

  • Menopause
  • Hypothyroidism
  • Male Hypogonadism
  • Growth Hormone Deficiency

By Route of Administration

  • Oral
  • Transdermal
  • Parenteral

By Distribution Channel

  • Hospitals Pharmacies
  • Retail Pharmacies & Drug Stores
  • Online Pharmacies

By Geography

  • North America (By Therapy Type, By Indication, By Route of Administration, By Distribution Channel, and By Country)
    • U.S.
    • Canada
  • Europe (By Therapy Type, By Indication, By Route of Administration, By Distribution Channel, and By Country/Sub region)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Therapy Type, By Indication, By Route of Administration, By Distribution Channel, and By Country/Sub region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Therapy Type, By Indication, By Route of Administration, By Distribution Channel, and By Country/Sub region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Therapy Type, By Indication, By Route of Administration, By Distribution Channel, and By Country/Sub region)
    • GCC
    • South Africa
    • Rest of the Middle East and Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Pipeline Analysis, By Key Players
  • 4.2. Key Industry Developments - Mergers, Acquisitions, and Collaborations
  • 4.3. New Product Launches, By Key Players
  • 4.4. Impact of COVID-19 on the Global Hormone Replacement Therapy Market

5. Global Hormone Replacement Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Therapy Type
    • 5.1.1. Estrogen and Combinations Replacement Therapy
    • 5.1.2. Thyroid Hormone Replacement Therapy
    • 5.1.3. Growth Hormone Replacement Therapy
    • 5.1.4. Testosterone Hormone Replacement Therapy
  • 5.2. Market Analysis, Insights and Forecast - By Indication
    • 5.2.1. Menopause
    • 5.2.2. Hypothyroidism
    • 5.2.3. Male hypogonadism
    • 5.2.4. Growth hormone deficiency
  • 5.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.3.1. Oral
    • 5.3.2. Transdermal
    • 5.3.3. Parenteral
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospitals Pharmacies
    • 5.4.2. Retail Pharmacies & Drug Stores
    • 5.4.3. Online Pharmacies
  • 5.5. Market Analysis, Insights and Forecast - By Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Hormone Replacement Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Therapy Type
    • 6.1.1. Estrogen and Combinations Replacement Therapy
    • 6.1.2. Thyroid Hormone Replacement Therapy
    • 6.1.3. Growth Hormone Replacement Therapy
    • 6.1.4. Testosterone Hormone Replacement Therapy
  • 6.2. Market Analysis, Insights and Forecast - By Indication
    • 6.2.1. Menopause
    • 6.2.2. Hypothyroidism
    • 6.2.3. Male hypogonadism
    • 6.2.4. Growth hormone deficiency
  • 6.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.3.1. Oral
    • 6.3.2. Transdermal
    • 6.3.3. Parenteral
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospitals Pharmacies
    • 6.4.2. Retail Pharmacies & Drug Stores
    • 6.4.3. Online Pharmacies
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Hormone Replacement Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Therapy Type
    • 7.1.1. Estrogen and Combinations Replacement Therapy
    • 7.1.2. Thyroid Hormone Replacement Therapy
    • 7.1.3. Growth Hormone Replacement Therapy
    • 7.1.4. Testosterone Hormone Replacement Therapy
  • 7.2. Market Analysis, Insights and Forecast - By Indication
    • 7.2.1. Menopause
    • 7.2.2. Hypothyroidism
    • 7.2.3. Male hypogonadism
    • 7.2.4. Growth hormone deficiency
  • 7.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.3.1. Oral
    • 7.3.2. Transdermal
    • 7.3.3. Parenteral
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospitals Pharmacies
    • 7.4.2. Retail Pharmacies & Drug Stores
    • 7.4.3. Online Pharmacies
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.5.1. U.K.
    • 7.5.2. Germany
    • 7.5.3. France
    • 7.5.4. Spain
    • 7.5.5. Italy
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Hormone Replacement Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Therapy Type
    • 8.1.1. Estrogen and Combinations Replacement Therapy
    • 8.1.2. Thyroid Hormone Replacement Therapy
    • 8.1.3. Growth Hormone Replacement Therapy
    • 8.1.4. Testosterone Hormone Replacement Therapy
  • 8.2. Market Analysis, Insights and Forecast - By Indication
    • 8.2.1. Menopause
    • 8.2.2. Hypothyroidism
    • 8.2.3. Male hypogonadism
    • 8.2.4. Growth hormone deficiency
  • 8.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.3.1. Oral
    • 8.3.2. Transdermal
    • 8.3.3. Parenteral
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospitals Pharmacies
    • 8.4.2. Retail Pharmacies & Drug Stores
    • 8.4.3. Online Pharmacies
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.5.1. Japan
    • 8.5.2. China
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Hormone Replacement Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Therapy Type
    • 9.1.1. Estrogen and Combinations Replacement Therapy
    • 9.1.2. Thyroid Hormone Replacement Therapy
    • 9.1.3. Growth Hormone Replacement Therapy
    • 9.1.4. Testosterone Hormone Replacement Therapy
  • 9.2. Market Analysis, Insights and Forecast - By Indication
    • 9.2.1. Menopause
    • 9.2.2. Hypothyroidism
    • 9.2.3. Male hypogonadism
    • 9.2.4. Growth hormone deficiency
  • 9.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.3.1. Oral
    • 9.3.2. Transdermal
    • 9.3.3. Parenteral
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospitals Pharmacies
    • 9.4.2. Retail Pharmacies & Drug Stores
    • 9.4.3. Online Pharmacies
  • 9.5. Market Analysis, Insights and Forecast - By Country/ sub-region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Hormone Replacement Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Therapy Type
    • 10.1.1. Estrogen and Combinations Replacement Therapy
    • 10.1.2. Thyroid Hormone Replacement Therapy
    • 10.1.3. Growth Hormone Replacement Therapy
    • 10.1.4. Testosterone Hormone Replacement Therapy
  • 10.2. Market Analysis, Insights and Forecast - By Indication
    • 10.2.1. Menopause
    • 10.2.2. Hypothyroidism
    • 10.2.3. Male hypogonadism
    • 10.2.4. Growth hormone deficiency
  • 10.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.3.1. Oral
    • 10.3.2. Transdermal
    • 10.3.3. Parenteral
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospitals Pharmacies
    • 10.4.2. Retail Pharmacies & Drug Stores
    • 10.4.3. Online Pharmacies
  • 10.5. Market Analysis, Insights and Forecast - By Country/ sub-region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2026)
  • 11.2. Company Profiles
    • 11.2.1. Novo Nordisk A/S
      • 11.2.1.1. Overview
      • 11.2.1.2. Products & Services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Pfizer Inc.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products & Services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. AbbVie Inc.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products & Services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Merck KGaA
      • 11.2.4.1. Overview
      • 11.2.4.2. Products & Services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Endo Pharmaceuticals Solutions Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products & Services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Allergan
      • 11.2.6.1. Overview
      • 11.2.6.2. Products & Services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Eli Lilly and Company
      • 11.2.7.1. Overview
      • 11.2.7.2. Products & Services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Mithra Pharmaceuticals
      • 11.2.8.1. Overview
      • 11.2.8.2. Products & Services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Amgen
      • 11.2.9.1. Overview
      • 11.2.9.2. Products & Services
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Hormone Replacement Therapy Market Revenue (USD billion) Forecast, by Therapy Type, 2021-2034
  • Table 2: Global Hormone Replacement Therapy Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 3: Global Hormone Replacement Therapy Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 4: Global Hormone Replacement Therapy Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 5: Global Hormone Replacement Therapy Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 6: North America Hormone Replacement Therapy Market Revenue (USD billion) Forecast, by Therapy Type, 2021-2034
  • Table 7: North America Hormone Replacement Therapy Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 8: North America Hormone Replacement Therapy Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 9: North America Hormone Replacement Therapy Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 10: North America Hormone Replacement Therapy Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 11: Europe Hormone Replacement Therapy Market Revenue (USD billion) Forecast, by Therapy Type, 2021-2034
  • Table 12: Europe Hormone Replacement Therapy Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 13: Europe Hormone Replacement Therapy Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 14: Europe Hormone Replacement Therapy Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 16: Europe Hormone Replacement Therapy Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Asia Pacific Hormone Replacement Therapy Market Revenue (USD billion) Forecast, by Therapy Type, 2021-2034
  • Table 18: Asia Pacific Hormone Replacement Therapy Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 19: Asia Pacific Hormone Replacement Therapy Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 20: Asia Pacific Hormone Replacement Therapy Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 21: Asia Pacific Hormone Replacement Therapy Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 22: Latin America Hormone Replacement Therapy Market Revenue (USD billion) Forecast, by Therapy Type, 2021-2034
  • Table 23: Latin America Hormone Replacement Therapy Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 24: Latin America Hormone Replacement Therapy Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 25: Latin America Hormone Replacement Therapy Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 26: Latin America Hormone Replacement Therapy Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 27: Middle East & Africa Hormone Replacement Therapy Market Revenue (USD billion) Forecast, by Therapy Type, 2021-2034
  • Table 28: Middle East & Africa Hormone Replacement Therapy Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 29: Middle East & Africa Hormone Replacement Therapy Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 30: Middle East & Africa Hormone Replacement Therapy Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 31: Middle East & Africa Hormone Replacement Therapy Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 32: GCC Hormone Replacement Therapy Market Revenue (USD billion) Forecast, By Therapy Type, 2021-2034
  • Table 33: South Africa Hormone Replacement Therapy Market Revenue (USD billion) Forecast, By Therapy Type, 2021-2034
  • Table 34: Rest of Middle East & Africa Hormone Replacement Therapy Market Revenue (USD billion) Forecast, By Therapy Type, 2021-2034

List of Figures

  • Figure 1: Global Hormone Replacement Therapy Market Revenue Breakdown (USD billion, %) by Region, 2026 & 2034
  • Figure 2: Global Hormone Replacement Therapy Market Value Share (%), by Therapy Type, 2026 & 2034
  • Figure 3: Global Hormone Replacement Therapy Market Value Share (%), by Indication, 2026 & 2034
  • Figure 4: Global Hormone Replacement Therapy Market Value Share (%), by Route of Administration, 2026 & 2034
  • Figure 5: Global Hormone Replacement Therapy Market Value Share (%), by Distribution Channel, 2026 & 2034
  • Figure 6: Global Hormone Replacement Therapy Market Value (USD billion), by Region, 2026 & 2034
  • Figure 7: North America Hormone Replacement Therapy Market Value (USD billion), by Therapy Type, 2026 & 2034
  • Figure 8: North America Hormone Replacement Therapy Market Value Share (%), by Therapy Type, 2026
  • Figure 9: North America Hormone Replacement Therapy Market Value (USD billion), by Indication, 2026 & 2034
  • Figure 10: North America Hormone Replacement Therapy Market Value Share (%), by Indication, 2026
  • Figure 11: North America Hormone Replacement Therapy Market Value (USD billion), by Route of Administration, 2026 & 2034
  • Figure 12: North America Hormone Replacement Therapy Market Value Share (%), by Route of Administration, 2026
  • Figure 13: North America Hormone Replacement Therapy Market Value (USD billion), by Distribution Channel, 2026 & 2034
  • Figure 14: North America Hormone Replacement Therapy Market Value Share (%), by Distribution Channel, 2026
  • Figure 15: North America Hormone Replacement Therapy Market Value (USD billion), By Country, 2026 & 2034
  • Figure 16: North America Hormone Replacement Therapy Market Value Share (%), By Country, 2026
  • Figure 17: Europe Hormone Replacement Therapy Market Value (USD billion), by Therapy Type, 2026 & 2034
  • Figure 18: Europe Hormone Replacement Therapy Market Value Share (%), by Therapy Type, 2026
  • Figure 19: Europe Hormone Replacement Therapy Market Value (USD billion), by Indication, 2026 & 2034
  • Figure 20: Europe Hormone Replacement Therapy Market Value Share (%), by Indication, 2026
  • Figure 21: Europe Hormone Replacement Therapy Market Value (USD billion), by Route of Administration, 2026 & 2034
  • Figure 22: Europe Hormone Replacement Therapy Market Value Share (%), by Route of Administration, 2026
  • Figure 23: Europe Hormone Replacement Therapy Market Value (USD billion), by Distribution Channel, 2026 & 2034
  • Figure 24: Europe Hormone Replacement Therapy Market Value Share (%), by Distribution Channel, 2026
  • Figure 25: Europe Hormone Replacement Therapy Market Value (USD billion), By Country/ Sub-region, 2026 & 2034
  • Figure 26: Europe Hormone Replacement Therapy Market Value Share (%), By Country/ Sub-region, 2026
  • Figure 27: Asia Pacific Hormone Replacement Therapy Market Value (USD billion), by Therapy Type, 2026 & 2034
  • Figure 28: Asia Pacific Hormone Replacement Therapy Market Value Share (%), by Therapy Type, 2026
  • Figure 29: Asia Pacific Hormone Replacement Therapy Market Value (USD billion), by Indication, 2026 & 2034
  • Figure 30: Asia Pacific Hormone Replacement Therapy Market Value Share (%), by Indication, 2026
  • Figure 31: Asia Pacific Hormone Replacement Therapy Market Value (USD billion), by Route of Administration, 2026 & 2034
  • Figure 32: Asia Pacific Hormone Replacement Therapy Market Value Share (%), by Route of Administration, 2026
  • Figure 33: Asia Pacific Hormone Replacement Therapy Market Value (USD billion), by Distribution Channel, 2026 & 2034
  • Figure 34: Asia Pacific Hormone Replacement Therapy Market Value Share (%), by Distribution Channel, 2026
  • Figure 35: Asia Pacific Hormone Replacement Therapy Market Value (USD billion), By Country/ Sub-region, 2026 & 2034
  • Figure 36: Asia Pacific Hormone Replacement Therapy Market Value Share (%), By Country/ Sub-region, 2026
  • Figure 37: Latin America Hormone Replacement Therapy Market Value (USD billion), by Therapy Type, 2026 & 2034
  • Figure 38: Latin America Hormone Replacement Therapy Market Value Share (%), by Therapy Type, 2026
  • Figure 39: Latin America Hormone Replacement Therapy Market Value (USD billion), by Indication, 2026 & 2034
  • Figure 40: Latin America Hormone Replacement Therapy Market Value Share (%), by Indication, 2026
  • Figure 41: Latin America Hormone Replacement Therapy Market Value (USD billion), by Route of Administration, 2026 & 2034
  • Figure 42: Latin America Hormone Replacement Therapy Market Value Share (%), by Route of Administration, 2026
  • Figure 43: Latin America Hormone Replacement Therapy Market Value (USD billion), by Distribution Channel, 2026 & 2034
  • Figure 44: Latin America Hormone Replacement Therapy Market Value Share (%), by Distribution Channel, 2026
  • Figure 45: Latin America Hormone Replacement Therapy Market Value (USD billion), By Country/ Sub-region, 2026 & 2034
  • Figure 46: Latin America Hormone Replacement Therapy Market Value Share (%), By Country/ Sub-region, 2026
  • Figure 47: Middle East & Africa Hormone Replacement Therapy Market Value (USD billion), by Therapy Type, 2026 & 2034
  • Figure 48: Middle East & Africa Hormone Replacement Therapy Market Value Share (%), by Therapy Type, 2026
  • Figure 49: Middle East & Africa Hormone Replacement Therapy Market Value (USD billion), by Indication, 2026 & 2034
  • Figure 50: Middle East & Africa Hormone Replacement Therapy Market Value Share (%), by Indication, 2026
  • Figure 51: Middle East & Africa Hormone Replacement Therapy Market Value (USD billion), by Route of Administration, 2026 & 2034
  • Figure 52: Middle East & Africa Hormone Replacement Therapy Market Value Share (%), by Route of Administration, 2026
  • Figure 53: Middle East & Africa Hormone Replacement Therapy Market Value (USD billion), by Distribution Channel, 2026 & 2034
  • Figure 54: Middle East & Africa Hormone Replacement Therapy Market Value Share (%), by Distribution Channel, 2026
  • Figure 55: Middle East & Africa Hormone Replacement Therapy Market Value (USD billion), By Country/ Sub-region, 2026 & 2034
  • Figure 56: Middle East & Africa Hormone Replacement Therapy Market Value Share (%), By Country/ Sub-region, 2026
  • Figure 57: Global Hormone Replacement Therapy Market Share (%), By Company, 2026